The company’s shares closed 17% higher on Tuesday, at $0.034.
Respiri is a health technology player focused on developing innovative devices and mobile health apps to improve the management of chronic and costly respiratory disorders.
The company’s new partner Grey Innovation is a commercialisation technology company based in Melbourne, which is working with universities and research institutes in Australia and Germany.
Respiri has partnered with Grey Innovation to ensure fast completion and low execution risk for the upgraded breath sensor.
Respiri’s flagship product AirSonea is an easy-to-use device that connects via Bluetooth with a sophisticated smartphone app to detect and measure wheeze.
The company has a first-mover advantage in providing broad access to its proprietary acoustic based clinical solutions for remote monitoring using over-the-counter connected devices.
Respiri products have been cleared for use by the U.S. FDA, the European Union, the Australian TGA and the commencement of an approval process for Asian markets has begun.